Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 15/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021373 | 0.86 | HDAC1 (0.46) | HDAC1HDAC6CYP2D6CXCR4CHRM3 | |
| SCHEMBL1698225 | 0.86 | HDAC1 (0.40) | HDAC1HDAC6CYP2D6CXCR4CHRM3 | |
| SCHEMBL3311293 | 0.81 | HDAC1 (0.46) | HDAC1HDAC6CYP2D6CXCR4PTGDR2 | |
| SCHEMBL24858718 | 0.80 | CYP2D6 (0.43) | HDAC1HDAC6CYP2D6CXCR4 | |
| SCHEMBL3314390 | 0.80 | HDAC1 (0.44) | HDAC1HDAC6CYP2D6CXCR4 | |
| SCHEMBL21202393 | 0.80 | CYP2D6 (0.43) | HDAC1HDAC6CYP2D6CXCR4 | |
| SCHEMBL3950796 | 0.79 | HDAC1 (0.43) | HDAC1HDAC6CYP2D6CXCR4 | |
| SCHEMBL14071365 | 0.78 | CYP2D6 (0.42) | HDAC1HDAC6CYP2D6CXCR4 | |
| SCHEMBL923694 | 0.78 | PTGDR2 (0.44) | HDAC1HDAC6CXCR4PTGDR2 | |
| SCHEMBL14037800 | 0.77 | CXCR4 (0.46) | HDAC1HDAC6CYP2D6CXCR4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933231-B2 | Organic compounds | GIVAUDAN SA | 2015-01-13 | — | — | US | disclosed |
| US-8933231-B2 | Organic compounds | GIVAUDAN SA | 2015-01-13 | — | — | US | disclosed |
| US-8933231-B2 | Organic compounds | GIVAUDAN SA | 2015-01-13 | — | — | US | disclosed |
| US-20130129655-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20130129655-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20130129655-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2013-05-23 | — | — | US | disclosed |
| EP-2584916-A1 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011161163-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161163-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011160254-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011160254-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129655-A1 | Organic Compounds | C9, C5, TRPA1 | HDAC1 939/4885HDAC6 1775/4885CYP2D6 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.